MX342007B - Composicion de farmaco conjugado. - Google Patents

Composicion de farmaco conjugado.

Info

Publication number
MX342007B
MX342007B MX2011004706A MX2011004706A MX342007B MX 342007 B MX342007 B MX 342007B MX 2011004706 A MX2011004706 A MX 2011004706A MX 2011004706 A MX2011004706 A MX 2011004706A MX 342007 B MX342007 B MX 342007B
Authority
MX
Mexico
Prior art keywords
cell
drug conjugate
conjugate composition
maytansinoid
human
Prior art date
Application number
MX2011004706A
Other languages
English (en)
Inventor
Zhang Wei
Amphlett Godfrey
Fleming Michael
Chih Hung-Wei
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of MX342007B publication Critical patent/MX342007B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a una composición líquida y una composición liofilizada que comprende una cantidad efectiva terapéuticamente de un conjugado que comprende un anticuerpo acoplado químicamente a un maytansinoide. La invención proporciona adicionalmente un método para destruir una célula en un humano que comprende administrar al humano cualquiera de las composiciones de modo que el anticuerpo enlace a la superficie de la célula y es activada la citotoxicidad del maytansinoide, con lo cual es destruida la célula.
MX2011004706A 2003-05-14 2004-05-14 Composicion de farmaco conjugado. MX342007B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47055003P 2003-05-14 2003-05-14
PCT/US2004/015376 WO2004110498A2 (en) 2003-05-14 2004-05-14 Drug conjugate composition

Publications (1)

Publication Number Publication Date
MX342007B true MX342007B (es) 2016-09-09

Family

ID=33551418

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015009315A MX369959B (es) 2003-05-14 2004-05-14 Composicion de farmaco conjugado.
MXPA05012259A MXPA05012259A (es) 2003-05-14 2004-05-14 Composicion de farmaco conjugado.
MX2011004706A MX342007B (es) 2003-05-14 2004-05-14 Composicion de farmaco conjugado.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2015009315A MX369959B (es) 2003-05-14 2004-05-14 Composicion de farmaco conjugado.
MXPA05012259A MXPA05012259A (es) 2003-05-14 2004-05-14 Composicion de farmaco conjugado.

Country Status (18)

Country Link
US (9) US7374762B2 (es)
EP (2) EP2281577B1 (es)
JP (1) JP4703566B2 (es)
KR (3) KR101441358B1 (es)
CN (2) CN1816356A (es)
AU (4) AU2004247015B2 (es)
BR (1) BRPI0410260A (es)
CA (3) CA2525553C (es)
CO (1) CO5700797A2 (es)
CR (3) CR20120384A (es)
EA (1) EA009285B1 (es)
EC (1) ECSP056159A (es)
IL (1) IL247788A0 (es)
MX (3) MX369959B (es)
NO (1) NO342209B1 (es)
NZ (1) NZ543498A (es)
WO (1) WO2004110498A2 (es)
ZA (1) ZA200510155B (es)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
DE60234094D1 (de) 2001-05-11 2009-12-03 Ludwig Inst For Cancer Res Ltd Spezifische bindungsproteine und ihre verwendung
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
KR101441358B1 (ko) * 2003-05-14 2014-09-24 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
CN101186613B (zh) * 2003-05-20 2014-09-17 伊缪诺金公司 含有新的美登素类的改进的细胞毒剂
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2005009369A2 (en) * 2003-07-21 2005-02-03 Immunogen, Inc. A ca6 antigen-specific cytotoxic conjugate and methods of using the same
US7834155B2 (en) * 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
ES2376556T3 (es) * 2004-03-24 2012-03-14 Abbott Biotherapeutics Corp. Utilización de la anticuerpos anti-alfa5beta1 para inhibir la proliferación de las células cancerosas.
NZ579482A (en) * 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
BRPI0515745A (pt) * 2004-12-09 2008-08-05 Centocor Inc imunoconjugados de antiintegrina, métodos e usos
EP2468304A3 (en) 2005-02-11 2012-09-26 ImmunoGen, Inc. Process for preparing stable drug conjugates
US20060233814A1 (en) 2005-04-15 2006-10-19 Immunogen Inc. Elimination of heterogeneous or mixed cell population in tumors
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
RU2422143C2 (ru) * 2005-07-15 2011-06-27 Анджиокем Инк. Усиление действия противораковых агентов
EP1917030A4 (en) * 2005-08-03 2011-03-09 Immunogen Inc IMMUNKONJUGATFORMULIERUNGEN
CN101237881B (zh) * 2005-08-03 2015-04-22 伊缪诺金公司 免疫偶联物剂型
AU2012211479B2 (en) * 2005-08-03 2015-06-11 Immunogen, Inc. Immunoconjugate formulations
MX2008002607A (es) * 2005-08-22 2008-03-19 Immunogen Inc Un conjugado citotoxico ca6 antigeno-especifico y metodos para utilizar el mismo.
CA2893252C (en) 2005-08-24 2018-05-29 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
EP1806365A1 (en) * 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
UA94264C2 (ru) 2006-04-21 2011-04-26 Новартис Аг Стабильная жидкая фармацевтическая композиция, которая содержит антагонистическое моноклональное антитело к cd40
KR101528939B1 (ko) * 2006-07-18 2015-06-15 사노피 암 치료를 위한 ｅｐｈａ2에 대한 길항제 항체
CA2658557C (en) 2006-08-14 2015-12-01 Xencor, Inc. Optimized antibodies that target cd19
PL2066349T3 (pl) 2006-09-08 2012-09-28 Medimmune Llc Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
CN101711284A (zh) 2007-01-25 2010-05-19 达娜-法勃肿瘤研究所 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
EP2162152A2 (en) * 2007-06-01 2010-03-17 Biogen Idec MA, Inc. Cripto binding molecules
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
PE20120259A1 (es) 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
ES2609915T3 (es) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
EP2638907A3 (en) 2008-03-18 2014-05-14 Genentech, Inc. Combinations of an anti-HER2 antibody-drug conjugate and lapatinib
BRPI0910557A2 (pt) * 2008-04-18 2015-09-29 Angiochem Inc composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
US20100092495A1 (en) * 2008-04-30 2010-04-15 Immunogen Inc. Potent cell-binding agent drug conjugates
WO2010027766A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
EP2346906A4 (en) 2008-10-15 2013-04-24 Angiochem Inc CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
WO2010126552A1 (en) * 2009-04-30 2010-11-04 Immunogen, Inc. Potent cell-binding agent drug conjugates
KR101947176B1 (ko) 2009-06-03 2019-02-12 이뮤노젠 아이엔씨 접합 방법
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
WO2011050180A1 (en) * 2009-10-21 2011-04-28 Immunogen, Inc. Novel dosing regimen and method of treatment
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
EP2526118A4 (en) * 2010-01-21 2013-11-13 Immunogen Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF EGG CANCER
AU2011215900A1 (en) 2010-02-10 2012-07-26 Immunogen, Inc. CD20 antibodies and uses thereof
IL290617B2 (en) 2010-02-24 2023-11-01 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
AR083034A1 (es) * 2010-09-17 2013-01-30 Baxter Int ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO
US8790649B2 (en) * 2010-10-29 2014-07-29 Immunogen, Inc. EGFR-binding molecules and immunoconjugates thereof
EA201390575A1 (ru) * 2010-10-29 2014-01-30 Иммьюноджен, Инк. Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
WO2012065161A2 (en) 2010-11-12 2012-05-18 Scott & White Healthcare Antibodies to tumor endothelial marker 8
EP2663647A4 (en) 2011-01-14 2015-08-19 Redwood Bioscience Inc POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
MY171008A (en) 2011-03-29 2019-09-23 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
EP2691155B1 (en) 2011-03-29 2018-11-14 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
TR201802659T4 (tr) 2011-04-01 2018-03-21 Immunogen Inc Folr1 kanser terapisinin etkinliğini arttırmak için yöntemler.
WO2012154809A1 (en) * 2011-05-09 2012-11-15 University Of Virginia Patent Foundation Compositions and methods for treating cancer
CN103781491A (zh) * 2011-05-17 2014-05-07 索利吉尼克斯公司 热稳定性疫苗组合物及其制备方法
US9089529B2 (en) 2011-10-25 2015-07-28 Prothena Therapeutics Limited Antibody formulations and methods
US20130287797A1 (en) 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
WO2013171287A1 (en) 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
JP2015517512A (ja) 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体の更なる薬剤との併用
CN102746372B (zh) * 2012-07-19 2014-08-13 陕西佰傲再生医学有限公司 一种细胞外基质冷冻干燥保护液及其使用方法
KR20200079565A (ko) 2012-08-31 2020-07-03 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US10035817B2 (en) 2012-10-04 2018-07-31 Immunogen, Inc. Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
KR101491728B1 (ko) * 2012-12-14 2015-02-11 주식회사 휴메딕스 비타민 c와 비타민 b3의 컨쥬게이트 및 그를 포함하는 항산화제
US9605057B1 (en) * 2013-06-17 2017-03-28 Board Of Regents Of The University Of Texas System Endotrophin neutralization and use thereof
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CA2921975C (en) 2013-08-30 2024-02-13 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
KR102538993B1 (ko) 2013-10-15 2023-06-02 씨젠 인크. 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
LT3060256T (lt) * 2013-10-25 2019-07-10 Bayer Pharma Aktiengesellschaft Nauja stabili kompozicija
US9943606B2 (en) 2014-01-15 2018-04-17 Rutgers, The State University Of New Jersey Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
US10450363B2 (en) 2014-03-20 2019-10-22 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
GB2528643A (en) * 2014-07-08 2016-02-03 Adc Biotechnology Ltd Method of synthesising ADCs
MA40539A (fr) * 2014-09-02 2016-03-10 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicaments
PT3221346T (pt) 2014-11-21 2020-10-23 Bristol Myers Squibb Co Anticorpos compreendendo regiões constantes de cadeia pesada modificadas
LT3221363T (lt) 2014-11-21 2020-08-10 Bristol-Myers Squibb Company Antikūnai prieš cd73 ir jų panaudojimas
SG11201703760WA (en) 2014-11-25 2017-06-29 Bristol Myers Squibb Co Novel pd-l1 binding polypeptides for imaging
JP2018502067A (ja) 2014-12-04 2018-01-25 セルジーン コーポレイション 生体分子複合体
US10676773B2 (en) 2015-03-10 2020-06-09 Bristol-Myers Squibb Company Antibodies conjugatable by transglutaminase and conjugates made therefrom
ES2936317T3 (es) 2015-05-29 2023-03-16 Bristol Myers Squibb Co Anticuerpos contra OX40 y usos de los mismos
WO2016205367A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
JP6522806B2 (ja) * 2015-07-10 2019-05-29 シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． 抗体デュオカルマイシン薬物複合体を含む組成物
WO2017049149A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
US10584160B2 (en) 2015-09-23 2020-03-10 Bristol-Myers Squibb Company Glypican-3-binding fibronectin based scaffold molecules
CN108367043A (zh) 2015-12-04 2018-08-03 西雅图基因公司 季铵化的微管溶素化合物的缀合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
EA201891482A1 (ru) 2015-12-21 2018-12-28 Бристол-Маерс Сквибб Компани Модифицированные антитела для сайт-специфической конъюгации
EP3402465B1 (en) * 2016-01-13 2024-03-13 Genmab A/S Formulation for antibody and drug conjugate thereof
CA3016187A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
UA125510C2 (uk) 2016-03-25 2022-04-13 Сіджен Інк. Спосіб отримання пегильованої сполуки лікарський препарат-лінкер, де лікарським препаратом є ауристатин, та її проміжних сполук
AU2017257504A1 (en) 2016-04-26 2018-10-25 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US20190218294A1 (en) 2016-09-09 2019-07-18 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
FI3318281T3 (fi) * 2016-11-04 2023-03-21 Coriolis Pharma Res Gmbh Erittäin puhdistettuja sokereita ja sokerikoostumuksia
US20210330801A1 (en) * 2017-03-02 2021-10-28 Cadila Healthcare Limited Novel protein drug conjugate formulation
EP3600443A1 (en) 2017-03-24 2020-02-05 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
CN110719915A (zh) 2017-05-25 2020-01-21 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
TW201919710A (zh) * 2017-08-23 2019-06-01 日商第一三共股份有限公司 抗體－藥物結合物之製劑及其冷凍乾燥方法
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US20210292413A1 (en) * 2018-09-25 2021-09-23 Academia Sinica Anti-siglec antibody, pharmaceutical composition comprising the same, and uses thereof
JP2022513653A (ja) 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
LT3886914T (lt) 2018-11-30 2023-05-25 Bristol-Myers Squibb Company Antikūnas, apimantis lengvosios grandinės c gale esantį glutamino turintį prailginimą, jo konjugatus ir metodus bei panaudojimo būdus
US20220031860A1 (en) 2018-12-12 2022-02-03 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
CA3129901A1 (en) 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
WO2020234114A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft A novel stable high concentration formulation for anetumab ravtansine
AU2020309570A1 (en) 2019-07-10 2022-02-03 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
KR20220051332A (ko) 2019-07-10 2022-04-26 싸이브렉사 3, 인크. 치료제로서의 미세소관 표적화제의 펩티드 접합체
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN110974958B (zh) * 2019-12-25 2020-08-21 北京东方百泰生物科技有限公司 一种抗pd-l1单克隆抗体的注射制剂
WO2021136274A1 (zh) * 2019-12-30 2021-07-08 百奥泰生物制药股份有限公司 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2429001A (en) 1946-12-28 1947-10-14 Axel H Stone Artificial hand
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4563304A (en) * 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5196193A (en) * 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
DE69231123T2 (de) * 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
IL111748A0 (en) 1993-12-03 1995-01-24 Zeneca Ltd Proteins
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
ES2434840T3 (es) * 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US5714352A (en) * 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
NZ508873A (en) 1998-07-13 2003-10-31 Univ Texas Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
BRPI0017590B8 (pt) 1999-06-25 2021-05-25 Genentech Inc conjugado de maitansinoide - anticorpo anti-erbb, e formulação farmacêutica
EP2266607A3 (en) * 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
US6824780B1 (en) * 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
EP1242401B1 (en) * 1999-11-24 2006-12-27 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6596503B1 (en) 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
CA2436092A1 (en) 2001-01-29 2002-08-08 Idec Pharmaceutical Corporation Modified antibodies and methods of use
KR100863624B1 (ko) 2001-05-11 2008-10-15 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Ｃｄ26을 발현하는 세포와 연관된 질환의 치료제로사용되는 항-ｃｄ26 단클론항체
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) * 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
JP2005532258A (ja) 2002-01-03 2005-10-27 スミスクライン・ビーチャム・コーポレイション 免疫コンジュゲートの調製方法
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US20060246060A1 (en) * 2002-07-02 2006-11-02 Nesta Douglas P Novel stable formulation
KR101441358B1 (ko) * 2003-05-14 2014-09-24 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US11605302B2 (en) 2020-11-10 2023-03-14 Rockwell Collins, Inc. Time-critical obstacle avoidance path planning in uncertain environments

Also Published As

Publication number Publication date
MX369959B (es) 2019-11-27
WO2004110498A3 (en) 2005-08-04
AU2016216585A1 (en) 2016-09-01
EP1626740B1 (en) 2014-08-20
CO5700797A2 (es) 2006-11-30
CA2525553C (en) 2011-07-05
US20070009541A1 (en) 2007-01-11
ECSP056159A (es) 2006-04-19
EA200501810A1 (ru) 2006-06-30
US20070009539A1 (en) 2007-01-11
AU2011201150A1 (en) 2011-04-07
US20140294864A1 (en) 2014-10-02
JP2007533631A (ja) 2007-11-22
NO20055402D0 (no) 2005-11-15
US8012485B2 (en) 2011-09-06
US7501120B2 (en) 2009-03-10
NZ543498A (en) 2007-06-29
US20110300162A1 (en) 2011-12-08
IL247788A0 (en) 2016-11-30
US7374762B2 (en) 2008-05-20
CN1816356A (zh) 2006-08-09
EP1626740A2 (en) 2006-02-22
KR20130088907A (ko) 2013-08-08
CN102940889A (zh) 2013-02-27
US20070009540A1 (en) 2007-01-11
JP4703566B2 (ja) 2011-06-15
US20160367696A1 (en) 2016-12-22
EP2281577A2 (en) 2011-02-09
CA2525553A1 (en) 2004-12-23
CR8093A (es) 2008-11-26
US20190010229A1 (en) 2019-01-10
EP2281577B1 (en) 2016-11-16
KR20120073369A (ko) 2012-07-04
CA2930485A1 (en) 2004-12-23
CA2737127A1 (en) 2004-12-23
KR101441358B1 (ko) 2014-09-24
WO2004110498A2 (en) 2004-12-23
BRPI0410260A (pt) 2006-05-16
EP2281577A3 (en) 2012-01-25
NO342209B1 (no) 2018-04-16
US20090142361A1 (en) 2009-06-04
KR101424624B1 (ko) 2014-07-31
AU2004247015B2 (en) 2010-12-16
CA2930485C (en) 2018-04-10
AU2016216585B2 (en) 2017-11-23
US20040241174A1 (en) 2004-12-02
US7494649B2 (en) 2009-02-24
KR20060080535A (ko) 2006-07-10
MXPA05012259A (es) 2006-04-18
CR20120505A (es) 2012-11-21
US7514080B2 (en) 2009-04-07
CA2737127C (en) 2016-07-26
CR20120384A (es) 2016-12-02
AU2011201150B2 (en) 2013-10-10
NO20055402L (no) 2006-02-10
AU2004247015A1 (en) 2004-12-23
EA009285B1 (ru) 2007-12-28
AU2014200091B2 (en) 2016-05-26
AU2014200091A1 (en) 2014-01-23
ZA200510155B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
MX369959B (es) Composicion de farmaco conjugado.
AU2003301190A1 (en) Administration of capsaicinoids
WO2006058140A3 (en) Capsaicinoid gel formulation and uses thereof
UA103758C2 (ru) Конъюгаты олигомеров инсулина, их композиции и применение
MY129406A (en) Taste masked liquid pharmaceutical compositions
MXPA05006670A (es) Administracion de capsaicinoides.
GB2431346C (en) A combination composition comprising paracetamol and ibuprofen
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
WO2002013873A3 (en) P97-active agent conjugates and their methods of use
MXPA02010801A (es) Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados.
IL206830A (en) Use of an integrin-containing antagonist of the alpha 1 subunit - of the integrin to prepare a drug for the treatment of osteoporosis
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
MX347237B (es) Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
SG149872A1 (en) Antagonists of the bradykinin b1 receptor
DK1140198T3 (da) Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
AU2207197A (en) Targeted site specific drug delivery compositions and method of use
WO2005123113A3 (en) Interferon compositions and methods of use thereof
WO2005002516A3 (en) Leukocyte internalized peptide-drug conjugates
AU2001246388A1 (en) Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine
TNSN06113A1 (en) Antagonists of the bradykinin b1 receptor